Product image of Myastad (Mycophenolic Acid) supplied by GNH India

Myastad

Active Ingredient:
Mycophenolic Acid
Origin:
EU

Myastad (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myastad, is an immunosuppressant presented as an oral formulation for oral use. It is employed to lower the risk of organ transplant rejection and to treat lupus nephritis by inhibiting lymphocyte proliferation in transplant recipients and patients with autoimmune kidney disease.

GNH India supplies Myastad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Myastad, an antimetabolite immunosuppressant, is indicated for conditions where immune modulation is required.
  • Organ transplant rejection: reduces the likelihood of acute and chronic graft rejection in kidney, heart and liver transplant recipients.
  • Lupus nephritis: improves renal function and slows disease progression in patients with systemic lupus erythematosus affecting the kidneys.

How It Works

  • Mycophenolic Acid selectively inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis of guanosine nucleotides. By limiting guanosine availability, the drug impairs DNA synthesis in activated T and B lymphocytes, leading to reduced proliferation and diminished immune responses essential for transplant rejection and autoimmune activity.

Side Effects

Myastad may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: frequent loose stools.
  • Vomiting: occasional episodes.
  • Abdominal pain: cramping or discomfort.
  • Headache: transient mild pain.
  • Upper respiratory infections: increased susceptibility.

Serious or Rare Side Effects

  • Leukopenia or neutropenia: significant reduction in white blood cells.
  • Anemia: decreased red blood cell count.
  • Severe infections: opportunistic or systemic infections.
  • Hepatic dysfunction: elevated liver enzymes or hepatitis.
  • Malignancy risk: potential increased incidence of certain cancers.
  • Progressive multifocal leukoencephalopathy (PML): rare but serious brain infection.

Precautions & Warnings

  • Before initiating Myastad, clinicians should consider several safety measures.
  • Monitor blood counts: regular CBC to detect leukopenia or anemia.
  • Assess renal function: adjust dosing in impaired kidneys.
  • Avoid use in pregnancy: safety category unknown; weigh risks vs benefits.
  • Counsel on infection risk: advise patients to report signs of infection promptly.
  • Adjust for hepatic impairment: consider dose reduction in liver disease.
  • Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Myastad can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Live vaccines: may cause uncontrolled infection.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce drug exposure.
  • Antacids containing aluminum or magnesium: decrease absorption of mycophenolic acid.

Moderate Interactions (Monitor Closely)

  • Azathioprine: additive bone‑marrow suppression.
  • ACE inhibitors or ARBs: potential for increased nephrotoxicity.
  • NSAIDs: may exacerbate renal impairment.
  • Non‑live vaccines: monitor immune response.

Frequently Asked Questions

Myastad contains mycophenolic acid and is prescribed to prevent organ transplant rejection and to treat lupus nephritis. It works by suppressing the immune system, helping to protect transplanted organs and reduce kidney inflammation caused by lupus.

Mycophenolic acid inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for the synthesis of guanosine nucleotides in lymphocytes. By blocking this pathway, the drug limits DNA production in activated T and B cells, reducing their proliferation and overall immune activity.

The dose of Myastad is individualized by the prescribing clinician based on the patient’s condition, weight, renal function and other factors. Healthcare providers determine the appropriate regimen and adjust it as needed during therapy.

The safety of Myastad in pregnancy and lactation has not been established. Because mycophenolic acid may cause fetal harm, it is generally avoided in pregnant women unless the potential benefit justifies the risk. Breastfeeding is also not recommended without medical guidance.

To order Myastad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myastad (mycophenolic acid) belongs to the antimetabolite class, differing from calcineurin inhibitors like tacrolimus or cyclosporine. It offers a distinct mechanism by targeting nucleotide synthesis, which may result in a different side‑effect profile and can be used in combination with other agents for synergistic immunosuppression.

Myastad should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Maintaining these conditions helps preserve the drug’s stability and potency throughout its shelf life.

Myastad is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without medical advice.

Serious risks include severe bone‑marrow suppression (leading to leukopenia or anemia), opportunistic infections, liver toxicity, and rare occurrences of progressive multifocal leukoencephalopathy (PML). Patients should be monitored regularly for these complications.

Myastad is contraindicated in individuals with known hypersensitivity to mycophenolic acid or any of its excipients, in patients with active uncontrolled infections, and in those who are pregnant unless the benefit outweighs the risk. Clinicians should assess each patient’s medical history before prescribing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT